Polomar Health Services PMHS
OTC PMHS
$0.17 +0.00 (+0.00%)
At close: Sep 28, 2026 · 4:00 PM EDT

Polomar Health Services (PMHS) Notes Payables (2023 - 2026)

Updated

Polomar Health Services (PMHS) recorded Notes Payables of $794,787 in Q2 2026, up 33.0% from $597,550 a year earlier but down 3.0% from the prior quarter.

Analysis

Polomar Health Services (PMHS) Notes Payables (2023 - 2026) Analysis & Trends

At the end of FY2025, Polomar Health Services reported Notes Payables of $897,660, down 21.2% from FY2024.

  • Across earlier years, Notes Payables came in at $1.14 million in FY2024 and $32,484 in FY2023.
  • Quarterly Notes Payables has ranged from $32,484 in Q4 2023 to $1.3 million in Q1 2025 over the past five years.
  • Per Business Quant, the preceding three quarters came in at $818,952 (Q1 2026), $897,660 (Q4 2025) and $994,385 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Polomar Health Services 4.81 Mn 4.37 Mn 935,916.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 794,787.00
Mar 31, 2026 818,952.00
Dec 31, 2025 897,660.00
Sep 30, 2025 994,385.00
Jun 30, 2025 597,550.00
Mar 31, 2025 1.30 Mn
Dec 31, 2024 1.14 Mn
Sep 30, 2024 33,849.00
Dec 31, 2023 32,484.00
API Access

Polomar Health Services Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=PMHS&period=max&api_key=YOUR_API_KEY